NCT06917339 Retrospective Analyses of TrakStar Database
| NCT ID | NCT06917339 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Neuronetics |
| Condition | Depression |
| Study Type | OBSERVATIONAL |
| Enrollment | 156,000 participants |
| Start Date | 2025-02-25 |
| Primary Completion | 2035-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 156,000 participants in total. It began in 2025-02-25 with a primary completion date of 2035-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, real-world data will be used to better understand the effects patient characteristics, symptoms and TMS protocol parameters have on clinical outcomes with NeuroStar TMS.
Eligibility Criteria
Inclusion Criteria: * Male or female reported in database and not an invalid entry * Age reported and not an invalid entry * Treatment date of November 01, 2008 or later. Exclusion Criteria: • Incomplete information on treatment parameters
Contact & Investigator
Eleanor Cole, PhD
STUDY DIRECTOR
Neuronetics
Frequently Asked Questions
Who can join the NCT06917339 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 120 Years, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06917339 currently recruiting?
Yes, NCT06917339 is actively recruiting participants. Contact the research team at neha.goyal@neurostar.com for enrollment information.
Where is the NCT06917339 trial being conducted?
This trial is being conducted at Malvern, United States.
Who is sponsoring the NCT06917339 clinical trial?
NCT06917339 is sponsored by Neuronetics. The principal investigator is Eleanor Cole, PhD at Neuronetics. The trial plans to enroll 156,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.